Acadia Pharmaceuticals Inc.
Clinical trials sponsored by Acadia Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company developing treatments for central nervous system disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for tough depression? drug trial targets Non-Responders
Symptom relief Recruiting nowThis study tests a new medicine called ACP-211 in adults with major depression who haven't gotten better with standard antidepressants. About 153 people will receive either the drug or a placebo for 28 days. The main goal is to see if ACP-211 reduces depression symptoms more than…
Phase: PHASE2 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New pill aims to quiet hallucinations in Alzheimer's patients
Symptom relief Recruiting nowThis clinical trial tests a drug called ACP-204 to see if it can reduce hallucinations and delusions in people with Alzheimer's disease. The study will involve over 1,000 adults aged 55 to 95 who have Alzheimer's and psychosis. Participants will receive either ACP-204 or a placeb…
Phase: PHASE2, PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
New hope for dementia psychosis: experimental drug ACP-204 enters key trial
Symptom relief Recruiting nowThis study tests whether the experimental drug ACP-204 can reduce psychosis symptoms like hallucinations and delusions in people with Lewy body dementia. About 180 adults aged 55 to 85 will take either ACP-204 or a placebo daily for 6 weeks. The goal is to see if the drug safely …
Phase: PHASE2 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC